KROSHealthcareMicro-Cap
Keros Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Keros Therapeutics, Inc. (KROS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are KROS insiders buying or selling?
Keros Therapeutics, Inc. insiders reported 18 open-market buys ($55.7M) and 55 sells ($242.6M) across 73 Form 4 filings — a net selling position of $186.9M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 17, 2026)
Total Form 4 filings
73
SEC EDGAR
Insider filers
20
Insider buys (18)
$55.7M
Insider sells (55)
$242.6M
Insider sentiment
Net sellingNet insider flow of $186.9M in net selling. 3 insider buys in the last 90 days.
Recent KROS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.61 | $10.6K |
| Jun 17, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.19 | $10.2K |
| Jun 15, 2026 | Charles W. Newton | Director | Sale | 550 | $10.04 | $5.5K |
| Jun 8, 2026 | Nima Farzan | Director | Sale | 2.6K | $10.73 | $28.2K |
| Jun 8, 2026 | Julius Knowles | Director | Sale | 2.6K | $10.73 | $28.2K |
| Jun 5, 2026 | Alpna Seth | Director | Sale | 2.6K | $10.72 | $28.1K |
| May 19, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $10.58 | $10.6K |
| Apr 17, 2026 | Jean Jacques Bienaime | Director | Purchase | 1.0K | $11.70 | $11.7K |
| Mar 11, 2026 | Jean Jacques Bienaime | Director | Purchase | 2.0K | $11.21 | $22.4K |
| Feb 20, 2026 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | Sale | 7.0K | $16.17 | $113.4K |
| Feb 20, 2026 | Lorena Raquel Lerner | Chief Science Officer | Sale | 3.9K | $16.35 | $63.3K |
| Feb 20, 2026 | Esther Cho | SVP, General Counsel | Sale | 4.7K | $16.35 | $77.6K |
| Feb 20, 2026 | Keith Regnante | CHIEF FINANCIAL OFFICER | Sale | 4.7K | $16.35 | $77.5K |
| Oct 17, 2025 | Kariv Tomer | 10% Owner | Sale | 4.8M | $17.75 | $85.0M |
| Oct 15, 2025 | Daniel Schneeberger | 10% Owner | Sale | 5.4M | $17.75 | $95.7M |
| Apr 12, 2025 | Daniel Schneeberger | 10% Owner | Purchase | 934.3K | $10.13 | $9.5M |
| Jan 24, 2025 | Keith Regnante | CHIEF FINANCIAL OFFICER | Sale | 40.0K | $45.29 | $1.8M |
| Aug 15, 2024 | Carl L Gordon | Director | Sale | 250.0K | $44.01 | $11.0M |
| Aug 15, 2024 | ORBIMED ADVISORS LLC | Director | Sale | 250.0K | $44.01 | $11.0M |
| Jan 8, 2024 | Keith Regnante | Chief Financial Officer | Sale | 40.0K | $45.29 | $1.8M |
| Jun 12, 2023 | Keith Regnante | Chief Financial Officer | Sale | 40.0K | $46.61 | $1.9M |
| Jan 20, 2023 | Julius Knowles | Director | Purchase | 1.2K | $20.98 | $25.0K |
| Jul 15, 2022 | Jennifer Lachey | Chief Scientific Officer | Sale | 1.9K | $30.00 | $57.5K |
| May 13, 2022 | Jennifer Lachey | Chief Scientific Officer | Sale | 5.3K | $41.90 | $222.0K |
| Apr 13, 2022 | Jennifer Lachey | Chief Scientific Officer | Sale | 5.3K | $62.77 | $332.7K |
Showing the 25 most recent of 73 Form 4 filings for Keros Therapeutics, Inc..
Most active KROS insiders
- Julius Knowles19 filings
- Jennifer Lachey16 filings
- Claudia Ordonez5 filings
- Jean Jacques Bienaime5 filings
- Keith Regnante4 filings
Ask anything about KROS insider activity
Use Trabud's AI agent to query Keros Therapeutics, Inc.'s Form 4 history in plain English — "Show me KROS CEO purchases this year" or compare it against any other ticker.
Open the AI agentKROS insider trading FAQ
Are Keros Therapeutics, Inc. insiders buying or selling?
Across 73 SEC Form 4 filings, Keros Therapeutics, Inc. (KROS) insiders reported 18 open-market purchases totaling $55.7M and 55 sales totaling $242.6M. That is a net selling position of $186.9M.
How many insiders trade KROS stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Keros Therapeutics, Inc.. The most recent filing was accepted on Jul 17, 2026.
Where does Trabud get KROS insider trading data?
All KROS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.